Which is a better pick?

GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis. The consensus recommendation for GlaxoSmithKline is a “buy.” Wall Street analysts expect an upside potential of 10.47% for GlaxoSmithKline based on the company’s closing price on June 26 and a target price of $44.33. Out of four analysts covering GlaxoSmithKline, two recommend a “strong buy,” and two recommend a “hold.”

Wall Street analysts expect an upside potential of 5.87% for Novo Nordisk based on the company’s closing price on June 26 and a target price of $53.90. Only one analyst covers the company and has recommended a “hold.”

Stock price movements and valuation

On June 26, GlaxoSmithKline closed at $40.13, 1.23% lower than the previous close, 10.22% higher than its 52-week low price of $36.41, and 5.17% lower than its 52-week high price of $42.32. The company’s market capitalization is $100.96 billion, and its PE, forward PE, PE to growth (or PEG), price-to-sales (or PS), price-to-book (or PB), and price-to-cash ratios were 19.52x, 13.45x, 2.19x, 2.54x, 19.39x, and 18.87x, respectively.

On June 26, Novo Nordisk closed at $50.91, 0.53% lower than the previous close, 23.48% higher than its 52-week low price of $41.23, and 3.63% lower than its 52-week high price of $52.83. The company’s market capitalization is $95.51 billion and PE, forward PE, PEG, PS, and PB ratios were 21.19x, 18.09x, 2.30x, 5.53x, and 17.03x, respectively.

Compared to Novo Nordisk, GlaxoSmithKline is trading at lower PE, forward PE, PEG, and PS ratios, but higher PB ratio.

Latest articles

Apple Arcade (AAPL) is a subscription gaming service that was unveiled at Apple’s annual event last week. The service will launch on September 19.

Cannabis legalization is gaining traction not only in the US but also globally. The third presidential Democratic debate was held on September 12.

Google has agreed to make a one-time settlement of over $945 million euros to the French ministry. The ministry accused Google of evading taxes.

In Q4 2018, legendary investor George Soros sold all his holding in Apple (AAPL). In Q3 2018, Apple represented around 0.2% of his total portfolio.

Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.

Despite Aurora Cannabis's subdued results, Cowen initiated coverage on five cannabis stocks: CRLBF, GTBIF, CURLF, MMNFF, and ACRGF.